38615results about "Organic chemistry" patented technology

An organic molecule is disclosed comprising:a first chemical moiety with a structure of formula I,andtwo second chemical moieties, each at each occurrence independently from another consisting of a structure of formula II,wherein the first chemical moiety is linked to each of the two second chemical moieties via a single bond.

The invention discloses a novel synthetic method for 5-phenyl tetrazole, which includes the following steps: firstly performing acid neutralization to hydrazine hydrate; then adding mixing solution formed by cyanobenzene, water and ethyl alcohol to generate phenyl aminoguanidine salt; adopting sodium nitrite for diazotization to obtain nitrine amidine under the acidic condition; obtaining 5-phenyl tetrazole crude product through closed loop under the alkaline condition; obtaining 5-phenyl tetrazole acceptable product through adopting ethyl alcohol for refining. The method has the advantages of simple technology, simplicity in operation and high product yield.

Provided are a compound represented by formula (I) and a pharmaceutical composition comprising the compound, and a use of a compound of formula (A) for preventing and / or treating cancer, tumor, inflammatory disease, autoimmune disease, or immune-mediated disease.

The compounds represented by formula (I) of this invention exhibit excellent activity against a variety of pests and mites in agriculture or other fields. Furthermore, these compounds achieve good control effects at very low doses, and therefore can be used to prepare insecticides and / or acaricides.

Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Compounds or their pharmaceutically acceptable salts can modulate the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

Compounds or their pharmaceutically acceptable salts can modulate the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

An aqueous ultraviolet-absorbing resin emulsion, and an aqueous resin emulsion composition containing the emulsion is provided, wherein the emulsion is excellent in compatibility with a synthetic resin and light resistance. Also, the emulsion improves stability in blending with an aqueous emulsion of the synthetic resin, and prevents bleed out of the ultraviolet-absorbing resin on the surface of a coating film. Further, the aqueous ultraviolet-absorbing resin emulsion imparts excellent alkali or solvent resistance to a synthetic resin poor in alkali or solvent resistance. More specifically, an aqueous resin emulsion composition comprising (I) an aqueous ultraviolet-absorbing resin emulsion and (II) an other aqueous resin emulsion is provided, wherein the emulsion (I) is obtained by urethanizing (A) a polyol component having an ultraviolet-absorbing group {e.g., 1,1-bis[3-(2H-benzotriazol-2-yl)-4-hydroxy-benzeneethanol]methane}, (B) a polyol if necessary, (C) an alkyl or aryl dialkanolamine compound, and (D) an organic polyisocyanate in (E) an organic solvent, diluting the reaction mixture with (F) an organic solvent having a boiling point lower than 100° C. to give a resin solution, neutralizing the resin solution with (G) a neutralizing agent, and dispersing the resultant in water.

Provided herein, in part, is a compound of Formula (I)or a hydrate thereof,essentially free of one or more impurities, compositions thereof, and methods of use thereof.

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

The present application relates to a kind of dihydrocarbylimidazole biomimetic lipid compound and its preparation method and application, dihydrocarbylimidazole biomimetic lipid compound structure imitates natural phospholipid design, modification is not less than 10 carbon atoms alkyl on the 4th and 5th of imidazole, and modification is different alkyl chain length primary amine on 2nd position;Dihydrocarbylimidazole biomimetic lipid compound is mixed with therapeutic drug and other adjuvant, can be prepared to be loaded in the lipid nanoparticle of therapeutic drug, can be used as drug delivery system for the preparation of brain-targeted drug.Dihydrocarbylimidazole biomimetic lipid has the function of dynamic control blood-brain barrier, can realize the reversible opening of blood-brain barrier;Formed drug-loaded lipid composition can cross blood-brain barrier and better realize the brain-targeted delivery of loaded therapeutic drug;Drug-loaded lipid composition consisting of dihydrocarbylimidazole biomimetic lipid belongs to a new generation of biomimetic nanomedicine carrier, provides new strategy for realizing the brain-targeted delivery of different kinds of drugs.

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

Described herein, inter alia, are GTPase inhibitors and uses thereof.

The application discloses a compound and application thereof, and belongs to the technical field of biological pharmacy. The compound has a structure shown in formula (I), or a deuterium compound thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound has good PDE3 and / or PDE4 inhibiting effect, and is of great significance to the preparation of a medicine for PDE3 and / or PDE4 related diseases.

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D. Q61H, Q61L. Q61R or G12C. The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compormds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R. G13D, Q61H. Q61L, Q61R or G12C disorder.

Provided are crystalline and amorphous forms of (Compound 1), and pharmaceutically acceptable salts and compositions thereof, as well as the use of such for treating conditions associated with the inhibition of KRAS(G12D).

The present disclosure relates to compositions and methods for reversible fixation of biological samples using fixation reagents that form bis-carbamate crosslinks between amine-bearing moieties in biomolecules.

Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder

The preparation method comprises the following steps: mixing 20-40 parts by mass of substituted hydroxymethyl glycoluril, 45-85 parts by mass of mercaptocarboxylic acid and 0.5-3 parts by mass of an acidic catalyst, stirring and reacting for 1-10 hours at the temperature of 50-150 DEG C under the pressure condition of-0.01 to-0.1 MPa, adding 300-800 parts by mass of an organic solvent for diluting after the reaction is finished, washing and purifying with deionized water, and collecting an organic layer, thereby obtaining the mercaptan curing agent. Concentrating and drying to obtain the mercaptan curing agent. According to the thiol curing agent, the rigid glycoluril group is introduced, so that the rigidity of a cured product structure is improved, and the mechanical property, the adhesive property, the heat resistance and the damp-heat aging resistance of a cured product are improved; four tertiary amine groups in the substituted glycoluril have a certain self-promotion effect on a thiol curing epoxy reaction, and the curing reaction temperature is reduced under the condition that an accelerant is not added; the glycoluril-containing thiol epoxy resin curing agent disclosed by the invention has good application value and development prospect.

The invention belongs to the technical field of biological dyes, and discloses a bio-based melanin precursor compound, bio-based melanin as well as a preparation method and application of the bio-based melanin precursor compound and the bio-based melanin. The invention provides a bio-based melanin precursor compound 4-[5-(2, 2-diaminoethyl)-2, 3-dihydroxyphenyl]-1H-indole-5, 6-diphenol, and a preparation method of the bio-based melanin precursor compound. The bio-based melanin precursor compound is stable in chemical property and easy to store. And the catalyst can be used as a raw material to efficiently synthesize bio-based melanin through a catalytic oxidation reaction. The process for preparing the bio-based melanin is simple, mild, high in yield and suitable for large-scale industrial production. The bio-based melanin prepared by the invention has good application performance during dyeing, does not generate harmful substances, and is safe and environment-friendly.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful for treating subjects having a disorder or disease that can be treated by reducing the level of VAV1, such as cancer, inflammatory or autoimmune disorders.

A composition for an organic optoelectronic device, an organic optoelectronic device, and a display device, the composition including a first compound represented by Chemical Formula I, a second compound represented by Chemical Formula II, and a third compound represented by a combination of Chemical Formula III and Chemical Formula IV,